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BrazilThe study investigated the genetic relationship of carbapenem-resistant Acinetobacter baumannii clinical
isolated from inpatients during 2008–2011 from 11 Brazilian states. Antimicrobial susceptibility proﬁle was
determined by disc diffusion method and Etest. Polymerase chain reaction was applied for carbapenemase
genes, and ISAba1. Isolates were subjected to pulsed ﬁeld gel electrophoresis (PFGE) and multilocus sequence
typing (MLST) formolecular typing. Most of the isolates showed high resistance rates to antibiotics tested. The
blaOXA-51-like gene was found in all isolates, and 146 (94.2%) isolates were positive for blaOXA-23-like. In the most
OXA-23–producing isolates, the blaOXA-23-like gene was accompanied by ISAba1. A total of 146 OXA-23–
producing isolates were clustered into 28 genotypes by PFGE. Molecular analysis by MLST identiﬁed 13
sequence types (STs). The most prevalent PFGE proﬁles were designated as ST15 (CC15), ST1 (CC1), and ST79
(CC79). This study showed the widespread of clonal complexes of A. baumannii harboring the blaOXA-23-like
gene in different Brazilian states.uropean Congress of Clinical
y, 2013 [ePoster VI session,
: +55-2125621634.© 2014 Elsevier Inc. All rights reserved.1. Introduction
Acinetobacter baumannii is an opportunistic pathogen increasingly
affecting severely ill patients. This microorganism is highly capable of
surviving and spreading in the hospital environment and to develop
resistance to antimicrobial agents. In the last years, carbapenem
resistance has been reported among A. baumannii isolates and is often
associated to infections with high morbidity and mortality rates.
Carbapenem-hydrolysing class D β-lactamases of the oxacilinases are
the most important cause of carbapenem resistance in A. baumannii
worldwide (Poirel and Nordmann, 2005, Poirel and Nordmann, 2006
and Zarrilli et al., 2013).
In Brazil, A. baumannii has become particularly problematic
because of its prevalence and the carbapenems resistance, usually
related to oxacilinases, mostly involving OXA-23 producers, with
reports of local outbreaks since the late 90s (Carvalho et al., 2009;
Dalla-Costa et al., 2003). The ﬁrst report of A. baumannii resistant to
carbapenems was in 2003 with the description of 8 isolates collected
from hospitalized patients hospitalized at 2 hospitals in the SouthernBrazil (Curitiba – Paraná State). These isolates were OXA-23 pro-
ducers andwere part of the same clone, demonstrating the occurrence
of inter-hospital spread in that city (Dalla-Costa et al., 2003). In 2009,
we described the spread of multidrug resistance (MDR) OXA-23–
producing A. baumannii clones in the city of Rio de Janeiro: 2 clones
were prevalent, one being scattered at 7 hospitals and the second one
in other 5 hospitals (Carvalho et al., 2009). In the following years, this
microorganism has been identiﬁed in other Brazilian states.
Molecular epidemiological studies are important tools to clarify
the dissemination of MDR A. baumannii, to understand epidemic
dynamics and to identify the most efﬁcient control measures. Thus,
this study aimed to characterize carbapenem-resistant A. baumannii
isolates recovered in 11 Brazilian states over a 3-year period (2008–
2011), determining their genetic relationship by multilocus sequence
typing (MLST) analysis.
2. Materials and methods
2.1. Bacterial isolates
A total of 155 A. baumannii clinical isolates representing 11
Brazilian states belonging to 5 different geographical regions of this
country were included. They were collected at the Universidade
Federal do Mato Grosso do Sul (UFMS)/Mato Grosso do Sul (MS)
(n = 9) and Central Public Health Laboratories (LACENs) of Alagoas
(AL) (n = 2), Amazonas (AM) (n = 1), Bahia (BA) (n = 1), Distrito
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58), Minas Gerais (MG) (n = 8), Rio de Janeiro (RJ) (n = 44), Rio
Grande do Norte (RN) (n = 3), and Santa Catarina (SC) (n = 1) from
February 2008 to January 2011 (1 per patient). The most frequent
sites of isolation for these isolates were blood (18.7%), respiratory
tract secretions (18.0 %), catheter (13.5%), and urine (3.9%).
2.2. Identiﬁcation and antimicrobial susceptibility testing
A. baumannii isolates were identiﬁed by classical biochemical
techniques, ampliﬁcation of the rpoB (Gundi et al., 2009) and
blaOXA-51-like gene, and by ampliﬁed ribosomal DNA restriction analysis
(Vaneechoutte et al., 1995). The disc diffusion method was used to
evaluate susceptibility to the antimicrobial agents according to Clinical
and Laboratory Standards Institute guidelines (CLSI, 2012). MIC values
for imipenem, meropenem, polymyxin B, and tigecycline were
determined by Etest (AB Biodisk, Solna, Sweden) (CLSI, 2012).
2.3. Molecular investigations
A multiplex polymerase chain reaction (PCR) was used to detect
genes encoding the OXA-like carbapenemases OXA-23, OXA-24, OXA-
51, OXA-58, and OXA-143 (Higgins et al., 2010). Additional screening
of other carbapenemase encoding genes (blaKPC, blaNDM) and insertion
sequence ISAba1was performed by PCR (Naas et al., 2008, Nordmann
et al., 2011; Turton et al., 2006). To determine whether ISAba1 was
present upstream of blaOXA-51-like and blaOXA-23-like gene, PCRmapping
experiments using ISAba1 forward/OXA-51–like reverse or OXA-23–
like reverse primers (ISAba1F/OXA-51-likeR or OXA-23-likeR PCR)
were performed (Pagano et al., 2013; Chaulagain et al., 2012).
Pulsed ﬁeld gel electrophoresis (PFGE) typing was performed
using ApaI restriction enzyme (Carvalho et al., 2009). DNA fragments
were separated on 1% (w/v) agarose gels in 0.5% Tris-borate-EDTA
buffer using a CHEF DRIII apparatus (Bio-Rad, Hercules, CA, USA). The
patterns obtained were analysed by BioNumerics v.4.0 (Applied
Maths, Sint-Martens-Latem, Belgium) with Dice similarity coefﬁcient
analysis. The unweighted-pair group method using average linkages
was applied, and the bandwidth tolerance was set at 1.5%. Isolates
clustering together with 85% level of similarity were considered to
belong to the same genotype.
Isolates representing OXA-23–producing A. baumannii PFGE clones
were further tested by the MLST scheme developed by the Institute
Pasteur (www.pasteur.fr/recherche/genopole/PF8/mlst/Abaumannii.
html) (Diancourt et al., 2010). DNA sequencing was performed with
Big Dye Terminator v.3.1 Cycle Sequencing Kit (Applied Biosystems,
Foster City, CA, USA) and analyzed using an ABI Prism 3100 genetic
analyser (Applied Biosystems) at the PDTIS-IOC DNA Sequencing
Platform. To determine the CCs (complex clonal), eBURST software
(http://eburst.mlst.net/) was used.
3. Results
3.1. Resistance patterns and screening of carbapenemase encoding genes
and insertion sequence ISAba1
According to the results of the antimicrobial susceptibility testing,
all antimicrobials tested showed elevated resistance rate, and the
most of the isolates were resistant to more than 5 different classes of
antibiotics. Ciproﬂoxacin, cefepime, and piperacillin/tazobactam
showed the highest resistance rate (99.4%, n = 154), followed by
ceftazidime (97.4%, n = 151), imipenem (95.5%, n = 148), merope-
nem (94.2%, n = 146), and ampicillin/sulbactam (93.5%, n = 145).
Sulfamethoxazole/trimethoprim showed the highest susceptibility
rate (23.9%, n = 37) followed by amikacin (11.6%, n = 18).
All isolates showed the presence of blaOXA-51-like gene, originally
intrinsic to A. baumannii, and none were positive for blaOXA-24-like,blaOXA-58-like, and blaOXA-143-like. The presence of blaOXA-23-like genewas
conﬁrmed in most carbapenem-resistant isolates (n = 146; 94.2%),
and the ISAba1 element was detected upstream of the blaOXA-23 gene
in almost all OXA-23–producing isolates. By additional screening,
genes encoding for KPC and NDM were not found.
By MIC results, all OXA-23–producing isolates were highly
resistant to carbapenem (MIC N32 μg/mL) except for 1 isolate that
showed an MIC of 2.0 μg/mL for meropenem. For polymyxin B, MIC
rangewas 0.19–0.50 μg/mL, andMIC50/MIC90 values were of 0.38/0.50
μg/mL, respectively. Considering tigecycline, MIC range was 0.19–6
μg/mL, and MIC50/MIC90 values were of 3/6 μg/mL, respectively.
Among the 9 isolates non-OXA-23-producing, 5 were resistant to
imipenem and/or meropenem, and the ISAba1 element was found
upstream of the blaOXA-51 gene by PCR mapping.
3.2. Molecular typing
Based on PFGE analysis, the 146 OXA-23–producing isolates were
clustered into 28 genotypes (Table 1). The most prevalent was Ab1
(37.4% of isolates; n = 58) found in 8 states belonging to different
geographical regions (DF, ES, GO, MG, RJ, RN, SC, andMS), followed by
Ab2 (18.7%; n = 29) found in GO and MS and genotype Ab3 (9.7%;
n = 15) found in 5 states (DF, ES, MG, RJ, and RN).
MLST performed on 44 isolates representing PFGE OXA-23–
producing clones, including isolates from each state, allowed us to
identify 13 sequence types (STs) as shown in the Table 1. Four new
STs were ﬁrst described in our study and were deposited in the MLST
database (ST316, ST317, ST318, and ST319). Themost prevalent PFGE
proﬁles Ab1, Ab2, and Ab3 were designated ST15, ST1, and ST79,
respectively. The ST1 was found in Midwest (GO, MS), Northeast
(RN), and Southeast (MG). In RJ, we also identiﬁed ST160 (genotype
Ab21), ST162, (genotype Ab8 and Ab9), ST188 (genotype Ab6), and
ST316 (genotype Ab20). In the North (AM), Midwest (MS), and
Southeast (MG, RJ), we also observed the ST25 (genotype Ab27,
Ab28, and Ab29).
By eBURST, we found 6 major complexes (CC1, CC15, CC25, CC33,
CC79, and CC162), which includedmainly single-locus variants or, less
commonly, double-locus variants (Fig. 1). Some STs described in this
study were singletons (ST107 and ST319). Phylogenetic analysis
showed that ST79 and ST15 belong to the CC79 and CC15,
respectively. The CC15 (ST15 and ST318) was described in 9 of 10
Brazilian states studied (AL, DF, ES, GO, MG, RJ, RN, SC, and MS)
belonging to the 4 different geographical regions of the country. The
OXA-23–producing isolates belonging CC79 (ST79) were found in 8 of
10 states (AL, DF, ES, GO,MS, MG, RJ, and RN). The ST1 and ST160were
grouped in CC1 observed in GO, MG, MS, RJ, and RN. Other CCs were
found into our isolates (CC25, CC33, and CC162) as observed in Fig. 1,
and the distribution of them may be observed in Fig. 2.
4. Discussion
This study described the resistance proﬁles and genetic related-
ness of CRAB isolates collected in different Brazilian hospitals during 3
years beginning in February 2008. In recent years, A. baumannii has
been commonly reported as resistant to multiple drugs, and the
resistance rates to imipenem, meropenem, ceftazidime, piperacillin/
tazobactam, ciproﬂoxacin, and gentamicin in Latin America seem to
be among the world's largest (Peleg et al., 2008). Antimicrobial
Surveillance Program involving Latin America, imipenem-resistant
Acinetobacter spp. rates increased from 6.4%, 12.6%, and 0.0% in the
1997–1999 to 84.9%, 71.4%, and 50.0% in 2008–2010, respectively, in
Argentina, Brazil, and Chile (Gales et al., 2012). A. baumanniiMDR has
also been reported in some countries in South America, such as Brazil,
Argentina, and Colombia (Fiorilli et al., 2010; Villegas et al., 2007). All
the A. baumannii clinical isolates included in this study were MDR,
Table 1
Molecular typing analysis and detection of ISAba1 of OXA-23–producing A. baumannii from different states in Brazil.
Genotype Isolate ST Allelic proﬁle CC States Year ISAba1-upstream blaOXA-51-like ISAba1-upstream blaOXA-23-like
CCBH4902 RJ 2009 + +
CCBH4971 GO 2009 − −
CCBH5233 ES 2009 − +
Ab1 CCBH5471 15 6-6-8-2-3-5-4 CC15 MS 2010 − +
CCBH5881 MG 2010 + +
CCBH6006 DF 2010 + +
CCBH6890 RN 2011 + +
CCBH6959 SC 2011 − +
Ab2 CCBH5343 1 1-1-1-1-5-1-1 CC1 GO 2009 − +
CCBH5468 MS 2010 − −
CCBH4808 RJ 2008 + +
CCBH5791 MG 2010 + +
Ab3 CCBH6009 79 26-2-2-29-4-5 CC79 DF 2010 + +
CCBH6872 ES 2010 − +
CCBH6887 RN 2011 − +
CCBH4818 RJ 2008 + +
Ab4 CCBH5231 79 26-2-2-29-4-5 CC79 ES 2009 − +
CCBH6554 AL 2010 − +
Ab5 CCBH5164 107 34-35-37-1-5-6-36 – ES 2009 − −
Ab6 CCBH5405 188 1-3-6-1-3-4-4 – RJ 2009 − +
Ab7 CCBH5470 79 26-2-2-2-29-4-5 CC79 MS 2010 + +
Ab8 CCBH4819 162 3-2-2-2-2-4-8 CC162 RJ 2008 − +
Ab9 CCBH4900 162 3-2-2-2-2-4-8 CC162 RJ 2009 − +
CCBH5472 MS 2010 − +
Ab10 CCBH5639 151 27-5-7-1-7-1-4 CC33 ES 2010 − +
Ab11 CCBH5792 1 1-1-1-1-5-1-1 CC1 MG 2010 + +
CCBH6893 RN 2011 − +
Ab12 CCBH5162 79 26-2-2-2-29-4-5 CC79 ES 2009 + +
Ab14 CCBH5337 79 26-2-2-2-29-4-5 CC79 GO 2009 − −
Ab15 CCBH5338 1 1-1-1-1-5-1-1 CC1 GO 2009 + −
Ab16 CCBH5642 79 26-2-2-2-29-4-5 CC79 ES 2010 + +
Ab17 CCBH5036 317 3-1-15-2-40-4-4 – ES 2009 − +
Ab19 CCBH5054 25 3-3-2-4-7-2-4 CC25 AM 2009 − −
Ab20 CCBH4816 316 3-1-6-2-4-1-5 – RJ 2008 + +
Ab21 CCBH4800 160 1-1-1-1-5-1-41 CC1 RJ 2008 + +
Ab22 CCBH5361 79 26-2-2-2-29-4-5 CC79 ES 2009 + +
Ab24 CCBH5790 318 6-6-8-2-3-5-5 CC15 MG 2010 + +
Ab25 CCBH4825 316 3-1-6-2-4-1-5 – RJ 2008 − +
Ab26 CCBH5258 319 3-1-2-2-7-1-5 – MG 2009 − +
Ab27 CCBH5255 25 3-3-2-4-7-2-4 CC25 MG 2009 + +
Ab28 CCBH4797 25 3-3-2-4-7-2-4 CC25 RJ 2008 − +
Ab29 CCBH5475 25 3-3-2-4-7-2-4 CC25 MS 2010 + +
Ab32 CCBH5218 318 6-6-8-2-3-5-5 CC15 MG 2009 + +
Ab33 CCBH6558 15 6-6-8-2-3-5-4 CC15 AL 2010 + +
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the clinical outcome of serious infections caused by such pathogens.
In this work, we noted that the carbapenem resistance mediated
by the enzyme OXA-23 was found in most isolates from different
Brazilian states, conﬁrming several reports of outbreaks A. baumannii
that have this mechanism of resistance (Carvalho et al., 2009).
According to Clímaco et al (2013), the spread of OXA-23 is most likely
due to mobile elements (i.e., plasmids, transposons, insertion
sequence). In previous report, we showed that the blaOXA-23 gene
was consistently associated with transposon, Tn2006, and was
chromosomally encoded in all carbapenem-resistant A. baumannii
isolates studied (Grosso et al., 2011). Our results also indicated that
some isolates carried the blaOXA-23-like gene with an ISAba1 upstream,
and these ﬁndings are in accordance with the results of other studies.
As previously demonstrated by European and Brazilian reports
(Pagano et al., 2013), the degree of carbapenem resistance in A.
baumannii isolates may be accentuated by the presence of promoter
sequences provided by ISAba1, leading to expression of the OXA-23.
Worldwide dissemination of the blaOXA-23 carbapenemase gene
has been associated with speciﬁc clones. The study revealed that the
most prevalent PFGE proﬁles Ab1 (n = 58 isolates) and other
genotypes (Ab1, Ab24, Ab32, and Ab33) belonged to CC15 (ST15 and
ST318) from 9 Brazilian states. According Diancourt et al. (2010), A.
baumannii belonging to ST15 have experienced evolutionary successand almost universally exhibit MDR phenotypes, which facilitated
their rapid clonal expansion during recent years. This complex has
been identiﬁed in several European countries, including Italy, Spain,
Greece, and Turkey (Di Popolo et al., 2011, Gogou et al., 2011; Villalon
et al., 2011).
In Latin America (Argentina and Brazil), OXA-23–producing A.
baumannii strains have been commonly reported as belonging to CC79
(Grosso et al., 2011, Martins et al., 2013; Stietz et al., 2013). We
characterized the CC79 in 8 Brazilian states representing the second
major clonal complex in the country, followed by CC1. This CC1 is
designated as the second major A. baumannii clone with a broad
international distribution (Karah et al., 2012). We and other previous
reports described the ST79 and ST15 in public and private hospitals in
RJ (Southeast) (Grosso et al, 2011; Martins et al., 2013). In the current
study, we showed that these STs were also disseminated along the
country over the past 3 years.
Despite of non-OXA-23-producing, we found 5 carbapenem-
resistant isolates, and these results may be explained by the presence
of the ISAba1 element upstream the blaOXA-51 gene. As reported by
other studies, the reduced susceptibility to carbapenems in non–OXA-
23 isolates may be mediated by gene blaOXA-51-like, which is normally
little expressed. However, the presence of the insertion sequence
ISAba1 or ISAba9 is required for increased expression associated with
other mechanisms such as reduced permeability of the outer
Fig. 1. Relatedness of OXA-23–producing A. baumannii STs by eBurst analysis. Each ST is represented by a dot in proportional size to the number of A. baumannii involved, considering
all data in the Pasteur database. STs related in this study are indicated by arrows.
Fig. 2. Geographical distribution of CCs detected in different Brazilian states.
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2009; Nordmann et al., 2011).
In conclusion, we report here the presence of MDR A. baumannii
carrying the same carbapenem-resistance determinant (blaOXA-23
gene) with clonal country widespread dissemination of CC15 and
CC79. These results conﬁrmed the wide geographical distribution of
OXA-23 among clinical carbapenem-resistant A. baumannii isolates in
Brazil. The dissemination of these major clusters of MDR A. baumannii
in different states harboring blaOXA-23 gene illustrated the success that
this organism has to acquire carbapenem resistance and emphasizes
the importance of having effective control measures. Until now, few
reports have focused on A. baumannii in all geographical regions of
Brazil, mainly descriptions of local outbreaks. This is the ﬁrst study
that attempt to determine the Brazilian countrywide spread of MDR A.
baumannii harboring the blaOXA-23 gene in different regions of Brazil.
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